Avience Biomedicals SME IPO Subscription Status

A subscription of 10.51x means the IPO received bids for 11 times the number of shares available. For every 11 applications, only 1 can receive an allotment.

Here is what each category number tells you:

NII at 13.43x: NII includes high net worth individuals applying above Rs 2 lakh. At 13.43x, allotment probability for NII applicants is very low. The bNII segment came in at 13.66x and sNII at 12.96x.

Retail at 15.23x: Retail investors applying up to Rs 2 lakh saw 15.23x subscription. Allotment in the retail category is done by lottery when oversubscription exceeds 1x. At 15.23x applications received, roughly 1 in 15 retail applicants can expect an allotment (~7%).

Based on the final subscription data, here is a realistic view of allotment probability by category.

Retail Category: Retail subscription came in at 15.23x based on shares applied and 15.23x based on applications. In the retail category, SEBI mandates a minimum of one lot per applicant when possible. Allotment is done by lottery. At 15.23x applications received, approximately 1 in 15 retail applicants can expect an allotment. Applying from multiple accounts does not improve individual chances but increases household probability if each account is eligible.

NII Category: NII allotment is proportional, not by lottery. At 13.43x, an NII applicant applying for the minimum NII lot can expect a very small proportional allotment. Larger NII applications receive proportionally more shares but the effective return per rupee invested is diluted significantly at this oversubscription level.

QIB Category: QIB allotment is discretionary and handled by the book running lead managers. Retail investors do not participate in this category.

Check the Avience Biomedicals SME IPO Allotment Status page from 23 June 2026 for your allotment result.

GMP for Avience Biomedicals SME stands at Rs 85.00 today, giving an estimated listing price of Rs 293.00 per share.

A subscription of 10.51x combined with a GMP of 40.87% is a strong combination heading into listing. QIB demand above 50x in particular tends to support listing sentiment, as institutional investors are seen as informed buyers.

Track live GMP on the Avience Biomedicals SME IPO GMP Today page or the IPOwiz Live IPO GMP Tracker.

Avience Biomedicals Limited, incorporated in June 2024, is an ISO-certified healthcare and biotechnology solutions company. The enterprise specializes in manufacturing, supplying, and exporting high-precision molecular diagnostic formulations, in-vitro diagnostics (IVD) rapid test kits, serology products, and automated biochemistry and hematology analyzers. Operating entirely on business-to-business (B2B) and business-to-government (B2G) frameworks, Avience provides cost-effective diagnostics to premier hospital networks, pathology labs, and research institutions.

For allotment results from 23 June 2026, visit the Avience Biomedicals SME IPO Allotment Status page. For listing day updates on 25 June 2026, download the IPOwiz App.